arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ENANTA PHARMACEUTICALS INC

ENTA
$13.77 ▲ +0.46 (+3.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

ENANTA PHARMACEUTICALS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -3.4%
Op. Margin -130.7%
ROIC -129.3%
FCF / Share None
Trailing P/E
Price / Book 4.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$65.32M
↓ -3.4%
Net Income Profit after all expenses
$-81.89M
↑ +29.4%
Operating Margin Operating profit as % of sales
-130.7%
↑ +27.4% 1th
FCF / Share Free cash flow per share
$0.28
↓ -91.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
6
Financial Health
31
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 59 quarters